AstraZeneca, Cellworks partner to develop tuberculosis combination therapies
Under the collaboration, Cellworks will leverage its proprietary predictive platform to model drug MDR-TB and rationally identify synergistic combinations with highest possible efficacy and lowest possible toxic burden